Clinical trials
T-cell Acute Lymphoblastic Leukemia clinical trials
Below are recruiting t-cell acute lymphoblastic leukemia clinical trials, each written for real people, not researchers. We’re tracking 127 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06514794RecruitingTeam says not enrollingPhase 2
CAR-T cell therapy for T-cell leukemia and lymphoma
This trial tests a new CAR-T cell therapy (WU-CART-007) made from donor cells that target a protein called CD7 on cancer cells. It is for children and adults with T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma that has come back or is still present after treatment.
Duarte, CaliforniaAges 1 year+ - NCT06904066RecruitingPhase 1
Custom T cells for blood cancers with specific mutations
This trial tests a personalized treatment where your immune cells are collected, modified to recognize unique cancer markers (neoantigens) from TP53 or RAS mutations, and returned to fight blood cancers like AML, MDS, or multiple myeloma.
Bethesda, MarylandAges 18–120 - NCT05621291Recruiting
Sequencing test to guide care after CD19 CAR T in kids
This study checks a DNA-based lab test (next-generation sequencing, or NGS) to monitor B-cell recovery after CD19 CAR T treatment in children and young adults. The goal is to see whether the test can help guide management while looking for remission and safe recovery.
Los Angeles, CaliforniaAges 1–25 - NCT07483476Recruiting
Cell-free DNA in children with new ALL
This study looks at a special blood test that measures cell-free DNA (tiny pieces of genetic material) in children with acute lymphoblastic leukemia (ALL). It aims to understand how this test might help monitor the disease, and it is for newly diagnosed children who haven't started treatment yet.
ParisAges Up to 18 years - NCT05702645Recruiting
Down syndrome long-term study after leukemia treatment
This study follows children and young adults with Down syndrome who have survived acute leukemia (ALL or AML) to learn about their longer-term health after treatment ends. It may help families and doctors understand what health problems to watch for and how to provide better follow-up care.
Birmingham, AlabamaAges 6–39 - NCT06137118RecruitingPhase 1/Phase 2
Study of AZD0486 for relapsed or refractory B-cell ALL
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
Birmingham, AlabamaAges 12 years+ - NCT07227584RecruitingPhase 2
ALL treatment for adolescents and young adults
This trial tests a standard chemotherapy regimen for people aged 18 to 50 with a type of leukemia called Philadelphia chromosome-negative acute lymphoblastic leukemia (ALL). It aims to see how well the treatment works for this age group.
Boston, MassachusettsAges 18–51 - NCT07763054Recruiting
Low-dose antifungal prevention for patients with low white blood cell counts
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent fungal infections in patients whose white blood cell counts are very low for more than a week. It may help patients who are at high risk for fungal infections and cannot take other antifungal drugs.
Hainan, HainanAges 18–75 - NCT03911128Recruiting
Treatment protocol for newly diagnosed childhood and young adult ALL
This trial tests a standard treatment plan (a protocol) for people aged 0 to under 46 with newly diagnosed ALL, a cancer of the blood and bone marrow. It may help by making sure patients receive the right therapy based on their specific ALL subtype.
AalborgAges birth–45 years - NCT04307576RecruitingPhase 3
Study for newly diagnosed ALL children and young adults
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
BrusselsAges birth–45 years - NCT05809284Recruiting
Understanding CAR T-cell therapy persistence in young patients with ALL
This study looks at why CAR T-cell therapy stops working in some children and young adults with leukemia. It aims to help doctors understand how to make this treatment last longer.
LondonAges Up to 25 years - NCT05092451RecruitingPhase 1/Phase 2
CD70-targeting NK cell therapy for blood cancer relapse
This study tests an immune therapy made from cord blood “NK cells” that are engineered to attack cells with a marker called CD70. It’s given after chemotherapy that reduces your blood and immune system, aiming to treat relapse or refractory (not responding) blood cancers.
Houston, TexasAges 12–80 - NCT06346912RecruitingEarly Phase 1
CAR-T cell therapy for relapsed B-cell blood cancers
This trial tests a special type of immune therapy called CD19-BAFF CAR-T cells for people whose B-cell acute lymphoblastic leukemia or B-cell non-Hodgkin lymphoma has come back or not responded to standard treatment. The therapy uses your own modified immune cells to target and kill cancer cells.
Hangzhou, ZhejiangAges 18 years+ - NCT07470073RecruitingEarly Phase 1
Universal CAR-T cell therapy for B-cell leukemia (ages 12-75)
This trial tests a new type of CAR-T cell therapy (called universal CAR-T) that targets CD19 and CD20 markers on cancer cells. It is for people aged 12 to 75 with B-cell acute lymphoblastic leukemia that has not responded to standard treatments or has come back after treatment.
Wuhan, HubeiAges 12–75 - NCT07246707RecruitingPhase 1
KSV01 injection for relapsed or refractory B-cell acute lymphoblastic leukemia
This trial tests an investigational drug called KSV01 for people with a type of blood cancer (B-cell acute lymphoblastic leukemia) that has come back or hasn't responded to standard treatments. It aims to see if the drug can help control the cancer.
HangzhouAges 18–80 - NCT07039877RecruitingPhase 2
Low-dose venetoclax with itraconazole and TACL for relapsed or refractory ALL
This trial tests a combination of low-dose venetoclax (a targeted cancer pill) plus itraconazole (an antifungal) and chemotherapy drugs for adults with acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to first treatment.
Monterrey, Nuevo LeónAges 16–45 - NCT07634653Recruiting
Strength Training for Kids with Newly Diagnosed Blood Cancer
This study tests whether strength training exercises during cancer treatment can help children with acute lymphoblastic leukemia or lymphoblastic lymphoma feel stronger and recover better. The research includes optional interviews with parents to understand how the program affects families.
Chapel Hill, North CarolinaAges 6 years+ - NCT05827549RecruitingPhase 2
Blinatumomab for relapsed ALL, matched by risk group
This Phase 2 study tests how well blinatumomab works for children and adults whose acute lymphoblastic leukemia (ALL) has come back. It also looks at whether results differ based on the patient’s relapse “risk group.”
DaeguAges 1–22 - NCT07532525RecruitingPhase 1
Pomalidomide after CAR T for B-cell cancer
This trial tests whether the drug pomalidomide, given as a pill, can help people with B-cell leukemia or lymphoma who have recently received CAR T-cell therapy. The goal is to see if pomalidomide can keep the cancer from coming back, and it may be an option for those whose cancer is not growing but still needs management.
Ann Arbor, MichiganAges 18 years+ - NCT06390319RecruitingPhase 2
Adding dasatinib or venetoclax for children with T-cell leukemia or lymphoma
This trial tests whether adding either dasatinib or venetoclax to standard chemotherapy can improve outcomes for children aged 1 to 18 with newly diagnosed T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma, or mixed phenotype acute leukemia. It compares the effects of these added drugs to help doctors find better treatment options.
San Diego, CaliforniaAges 1–18 - NCT03959085RecruitingPhase 3
Inotuzumab plus chemotherapy for high-risk childhood leukemia
This Phase 3 trial tests whether adding inotuzumab to standard post-induction chemotherapy improves outcomes for children and young teens with high-risk B-ALL, mixed phenotype acute leukemia (MPAL), or certain high-risk B-LLy. It may help by targeting leukemia cells more directly, but participation depends on specific age, lab results, and medical history rules.
Birmingham, AlabamaAges 12 months–25 years - NCT03081910RecruitingPhase 1
CAR T cells made from your own cells to treat CD5 tumors
This early-phase trial tests a type of immune-cell therapy (CAR T cells) made using T cells with a CD5-targeting “zipper” to treat certain relapsed T-cell cancers. The goal is to see if the treatment can help shrink or clear the cancer, especially enough to move toward a stem cell transplant plan.
Houston, TexasAges Up to 75 years - NCT03533816RecruitingPhase 1
Gamma delta T-cell infusion after stem cell transplant
This early-phase study tests giving a special immune-cell treatment after an allogeneic (donor) stem cell transplant, plus a medication given after transplant to help the new immune system work better. It may help prevent or treat cancer returning after transplant.
Westwood, KansasAges 18–65 - NCT03938987RecruitingPhase 1/Phase 2
CAR T-cell therapy for CD19-positive aggressive lymphoma or ALL
This trial tests a lab-made immune therapy (CAR T-cells) that targets CD19, a marker found on certain lymphoma and leukemia cells. It’s for people whose lymphoma or ALL came back or did not respond to standard treatments, with the goal of getting the treatment to attack the cancer.
Calgary, AlbertaAges 2–70
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
T-cell Acute Lymphoblastic Leukemia trials by city
Studies with a site in or near these metro areas.
T-cell Acute Lymphoblastic Leukemia trials by state
Studies with a site anywhere in these states.
Common questions
- Are there clinical trials for t-cell acute lymphoblastic leukemia?
- Yes. Clin2 currently lists 127 recruiting t-cell acute lymphoblastic leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a t-cell acute lymphoblastic leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a t-cell acute lymphoblastic leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
- B-cell Acute Lymphoblastic Leukemia
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- B-Cell Acute Lymphoblastic Leukemia, Adult
- B-Cell Lymphoblastic Leukemia
- B-Cell Lymphoblastic Leukemia/Lymphoma
- Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia
- Acute Lymphoblastic Leukemia
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.